Leucine enhances aerosol performance of naringin dry powder and its activity on cystic fibrosis airway epithelial cells.

[1]  E. Sorscher,et al.  Hesperidin stimulates cystic fibrosis transmembrane conductance regulator-mediated chloride secretion and ciliary beat frequency in sinonasal epithelium , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[2]  K. Amighi,et al.  Formulation strategy and use of excipients in pulmonary drug delivery. , 2010, International journal of pharmaceutics.

[3]  D. Schuster,et al.  The bioflavonoid compound, sinupret, stimulates transepithelial chloride transport in vitro and in vivo , 2010, The Laryngoscope.

[4]  G. Węgrzyn,et al.  Genistein: a natural isoflavone with a potential for treatment of genetic diseases. , 2010, Biochemical Society transactions.

[5]  N. Regamey,et al.  Targeting Inflammation in Cystic Fibrosis , 2009, Respiration.

[6]  A. Chuchalin,et al.  Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. , 2009, Pulmonary pharmacology & therapeutics.

[7]  D. Touw,et al.  Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  P. Russo,et al.  Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  Wei Feng,et al.  Effect of alcohol on the solubility of amino acid in water , 2009 .

[10]  A. Ammit,et al.  Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency , 2009, Pharmaceutical Research.

[11]  R. Gambari,et al.  Pyrogallol, an active compound from the medicinal plant Emblica officinalis, regulates expression of pro-inflammatory genes in bronchial epithelial cells. , 2008, International immunopharmacology.

[12]  R. Gambari,et al.  Anti-inflammatory effect of miglustat in bronchial epithelial cells. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  M. Karin,et al.  New EMBO Member’s Review THE EMBO JOURNAL , 2022 .

[14]  J. Castillo,et al.  Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. , 2008, Journal of agricultural and food chemistry.

[15]  J. Freyssinet,et al.  Exaggerated apoptosis and NF‐KB activation in pancreatic and tracheal cystic fibrosis cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  V. Bours,et al.  Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. , 2007, Biochemical pharmacology.

[17]  P. Wüthrich,et al.  Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation. , 2006, International journal of pharmaceutics.

[18]  N. Chew,et al.  Effect of amino acids on the dispersion of disodium cromoglycate powders. , 2005, Journal of pharmaceutical sciences.

[19]  M. Rafiee-Tehrani,et al.  The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles. , 2005, Journal of pharmaceutical sciences.

[20]  Kambiz Gilani,et al.  The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine. , 2004, International journal of pharmaceutics.

[21]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[22]  M. Regan,et al.  Interleukin 8 Secretion from Monocytes of Subjects Heterozygous for the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutation Is Altered , 2004, Clinical Diagnostic Laboratory Immunology.

[23]  Chao Quan,et al.  Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. , 2003, Bioorganic & medicinal chemistry.

[24]  M. Welsh,et al.  Development of cystic fibrosis and noncystic fibrosis airway cell lines. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[25]  Gerald B. Pier,et al.  Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.

[26]  N. Chew,et al.  Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance , 2001, Pharmaceutical Research.

[27]  R. Gaynor,et al.  Role of the NF-kappaB pathway in the pathogenesis of human disease states. , 2001, Current molecular medicine.

[28]  K. Grohmann,et al.  Biological properties of citrus flavonoids pertaining to cancer and inflammation. , 2001, Current medicinal chemistry.

[29]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.

[30]  M. Akabas.  Cystic Fibrosis Transmembrane Conductance Regulator , 2000, The Journal of Biological Chemistry.

[31]  John N. Staniforth,et al.  Enhancement of Small Particle Size Dry Powder Aerosol Formulations using an Ultra Low Density Additive , 1999, Pharmaceutical Research.

[32]  M. Karin.  The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases (*) , 1995, The Journal of Biological Chemistry.

[33]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[34]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[35]  J. Dore,et al.  Effects of flavonoids on the release of reactive oxygen species by stimulated human neutrophils. Multivariate analysis of structure-activity relationships (SAR). , 1993, Biochemical pharmacology.

[36]  M. Corey,et al.  Effects of long-term nutritional rehabilitation on body composition and clinical status in malnourished children and adolescents with cystic fibrosis. , 1985, The Journal of pediatrics.

[37]  L. Ward,et al.  Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease. , 1985, The American journal of clinical nutrition.

[38]  C. Tanford,et al.  The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale. , 1971, The Journal of biological chemistry.

[39]  J. Rice,et al.  Insulin-like Growth Factor-I Levels Predict Weight, Height and Protein Catabolism in Children and Adolescents with Cystic Fibrosis , 2009, Journal of pediatric endocrinology & metabolism : JPEM.

[40]  M. Konstan,et al.  The Role of Inhaled Corticosteroids in the Management of Cystic Fibrosis , 2009, Paediatric drugs.

[41]  A. Clément,et al.  Airway epithelial cell inflammatory signalling in cystic fibrosis. , 2008, The international journal of biochemistry & cell biology.

[42]  P. Seville,et al.  Spray-dried powders for pulmonary drug delivery. , 2007, Critical reviews in therapeutic drug carrier systems.

[43]  J. Raper,et al.  How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders? , 2004, Pharmaceutical Research.